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Pd-103 Radioactive Stent Dosimetry 
Abstract 
"Coronary artery disease is the leading cause ofmorbidity and mortality in the western 
world. Approximately 450,000 angioplasties are performed annually in the United States" (5). 
Angioplasty solves the immediate problem ofarterial blockage, but thirty-five to forty percent of 
those that undergo angioplasty are diagnosed with restenosis, which is the reblocking ofthe 
artery. Restenosis results in a societal cost of800 2,000 million dollars per year. Stents have 
become commonplace in angioplasty procedures. They prevent elastic recoil and can decrease 
restenosis by twenty-two to thirty-two percent. The main problem is that stents do not prevent 
neointimal hyperplasia. For this reason, radiation has been researched as a form of treatment. 
Preclinical trials have shown that using radiation in the dose range of 15-30 Gy can substantially 
reduce restenosis (5). 
Currently only Phosphorus-32 has been used on a stent in clinical trials. These trials 
concluded that a stent coated with radioactive phosphorus decreased the amount ofneointimal 
hyperplasia along the stent's length but not beyond the stent's ends where the radiation does not 
reach insignificant enough amounts. The research done for this project proposed using 
Palladium-I03 on the stent instead ofP-32. After various computer simulations using the Monte 
Carlo program MCNP, the results show that a Pd-l03 stent's dose is sufficient along the stent in 
comparison to the P-32 dose and does not decrease as rapidly beyond the end of the stent as the 
dose from P-32 stent. After several varying trials ofpoint source placements using MCNP, it 
was shown that palladium should provide a significant improvement over phosphorus. 
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Introduction 
"Coronary artery disease is the leading cause ofmorbidity and mortality in the western 
world" (5). Approximately 450,000 angioplasties are performed each year in the United States 
alone. About 30%-40% ofthe patients that undergo angioplasty are diagnosed with restenosis, 
which is the reblocking ofthe artery. The use ofcoronary stents can reduce the rate ofrestenosis 
to 22%-32%. The cost to society ofthis restenosis is estimated to be 0.8 to 2 billion dollars per 
year. Some preclinical studies have shown that using ionizing radiation in the dose range of 15­
30 Oy during or following angioplasty procedures could reduce restenosis to below 10%. (5) 
Background 
Arteries can be summarized as tubelike structures with several layers. Beginning with 
the inside most layer, the layers are the endothelium, intima, internal elastic nlembrane, media, 
external elastic membrane, and the adventitia. Proximal arteries usually have a diameter in the 
range of3-5 rnm. (5) Angioplasty is rarely performed in arteries with a normal diameter less 
than about 1.5 rnm, and ... stents are rarely placed in arteries whose normal diameter is smaller 
than about 3.0 rnm" (5). The lumen of the artery is the area within the tube through which the 
blood flows. 
At times the lumen becomes partially or totally blocked by the formation ofplaques 
called atherosclerosis. The blocking ofthe lumen compromises blood flow and oxygen delivery. 
"The plaque begins in the intima by deposits offatty debris from blood" (5), The build-up of 
plaque begins a process that eventually causes a complex lesion to develop "as the core of the 
fibrous atherosclerotic plaque necroses, calcifies, and hemorrhages. This causes reduction in 
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blood flow, platelet aggregation, and ultimately formation ofa thrombosis (blood clot) with 
consequent myocardial ischemia and/or infarction" (5). 
Angioplasty is used to increase the lumen diameter. A catheter is inserted in a distal 
artery or vein and threaded into the blocked blood vessel. Then either the plaque is cut or 
ablated away or a balloon is inflated to push the plaque out ofthe way. The cutting and ablating 
devices are usually only used when the artery is too blocked for the uninflated balloon to enter or 
when there is heavy calcification. "In these cases it may be necessary to remove tissue by 
cutting (artherectomy device), ablating (rotoblator), or 
vaporizing (laser)" (5). Since these methods can cause 
damage to the arterial wall, they are not usually used to 
obtain the final desired lumen diameter. (5) It has become 
fairly commonplace for an unexpanded stent to also be 
inserted into the artery with the balloon. The stent is 
expanded when the balloon in inflated as can be seen in 
figure 1. The stent remains in the blood vessel. The stent 
prevents elastic recoil that can be a problem when balloon 
angioplasty is performed alone without stent implantation 
since the blood vessels are elastic and tend to return to their 
original shape after the angioplasty stretches them. 
Restenosis can also be caused by other means than elastic recoil. One major problem is 
neointimal hyperplasia. When the balloon is inflated, it stretches the arterial wall and causes 
lesions of the atherosclerotic plaque, the intima, and sometimes the media. As the body heals the 
blood vessel, "over weeks the neointima becomes less cellular and the healing site begins to 
Figure 1: Stent Implantation (6) 
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resemble a fibrous plaque"(5). In most patients the increase in the lumen diameter as a result of 
the angioplasty outweighs the lumen narrowing caused by the neointimal hyperplasia, but in 
about 40% of the patients, the neointimal hyperplasia is excessive and causes restenosis within 
three to six months. (5) 
The use ofradiation within the blood vessel after balloon angioplasty has been suggested 
''to inactivate (prevent from dividing) most cells that otherwise could proliferate to produce 
neointimal formation" (2). It has been reported that approximately a 75% reduction in restenosis 
can be achieved when stenting is combined with a delivery of 8 to 30 Gy irradiation via an 
endovascular Iridium-192 sources. (3) These sources were located within a catheter that was 
inserted after the balloon angioplasty. The catheter based radiation causes some difficulties, 
including reduced arterial blood flow during the irradiation, and longer treatment times, which 
increase the risk of complication. Also, the catheter has to be aligned in the center of the blood 
vessel to provide uniform radiation to the entire vessel wall. Since stents are commonly 
implanted within the vessel and do not obstruct blood flow, research has been done of the 
efficacy of inserting a radioactive stent to provide the radiation dose needed. This paper will 
focus on the use ofradioactive stents. 
Currently Phosphorus-32 is the only radioactive material that has been used on implanted 
stents. Albiero et al. reported that patients treated with radioactive ~-emitting P-32 stents with 
an initial activity of0.75 to 12 IlCi had no restenosis within the stent. However, more than 40% 
had restenosis at the edges ofthe stent. This is most likely a result of the drastic decrease in 
radioactive activity beyond the end ofthe stent. (l) "The short range ofthe beta particles results 
in a more rapid dose falloffversus ... gamma sources" (5). Gamma emitters penetrate too far 
though and would deliver larger doses to normal tissue and staff. (5) "Low-energy x-ray emitters 
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· .. reduce these risks" (5). For this reason, the research ofthis project focused on the radiation 
dosimetry ofa stent irradiated with Palladium-l 03, an x-ray emitter. 
Methods 
The goal ofthis project was to determine the radiation dosimetry ofPd-l03. This was 
done using MCNP4b Monte Carlo simulation code 
with both electron and photon tallies. Enough 
histories were performed "to reduce the estimated 
standard deviation to less than 4% of the mean, except 
in the bins that were far from the stent" (4). Figure 2 
shows the wire frame stent that was used. The stent is 
composed of 1 00 micron thick stainless steel with an 
Figure 2: Wire Frame Stent with 192 holes. 
outer diameter of3.5 mm and length of 15 mm. There 
were 192 holes: 12 around and 16 in the axial direction. Point sources were placed at a depth of 
0.5 microns into steel (Figure 3b). The point sources were either placed on the inside surface or 
outside surface of the stent. There were a total of600-point sources: one at each comer and 
midway between struts. The stent was then surrounded completely by water. Cylindrical tally 
cells were then established to determine the dosimetry at various distances from the outer stent 
surface (Figure 3a). These distances were 0.1, 0.2, 0.5, 1.0, 2.0, 3.0, 4.0, and 5.0 mm from the 
stent surface. 
A program was also designed to determine the dosimetry's angular dependence. The area 
between struts was divided into tally cells with a middle at the angles of7.5, 15, 22.5, and 30 
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degrees as seen in Figure 4. This was only done for the distances from the stent of 0.1 and 0.2 
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(a) (b) 
Figure 3: Cross-section parallel to the x and z-axes in Figure 2. 





Figures 5, 6, and 7 show the graphical representation ofthe dosimetry obtained from 
MCNP4b. The stent whose dosimetry is shown in figure 5 had point sources located on the outer 
edge ofthe stent. The peaks on the graph represent areas directly over a strut containing a point 
source. The valleys are the holes between the struts. This has an affect until about 0.5 rnm when 
the dosimetry line becomes fairly uniform over the length ofthe stent. Figure 6 illustrates the 
affect the stainless steel has on the radiation penetration. Instead ofhaving peaks where the 
point sources are located, the peaks are flattened the width ofeach strut. The area between the 
struts still has a lower radiation dosage than the areas above the point sources. Figure 7 
combines the results in figures 5 and 6. There is not as wide a variation in the dose between the 
Figure 4: Tally cells for 
angular dependence. 
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peaks and valleys, but the peak effects from the sources on the outside ofthe stent are also 
evident. 
Figure 8 illustrates even better the affect the location of the tally cells with respect to the 
struts has on the magnitude of the dose. The tally cell directly above the strut at 30 degrees has 
the highest dose. The 15 degree tally cell receives radiation activity from the struts on either side 
so is higher than that ofthe 7.5 and 22.5 degree tally cells. 
The four graphs also illustrate the rapid dose decay beyond the ends ofthe stent. The 
dose decreases by a factor of 100 within 0.5 mm. Figure 9 sums them all up though in 
comparing stents coated with different radioactive materials. By showing the rate of radioactive 
activity decrease, the efficacy ofthe radioactive material in preventing neointimal hyperplasia 
beyond the end ofthe stents can more easily be compared. As the graph shows, Pd-l03 
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Figure 8: Pd-l03 point sources with angular 
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Figure 9: The relative dose at 0.5 mm from the stent 













The final figure (figure 10) shows another approach to preventing edge restenosis. By 
increasing the activity ofthe radioactive material at the edge ofthe stent, the radioactive activity 
magnitude will increase beyond the ends ofthe stent. Figure 10 illustrates the dosimetry ofa P­
32 stent with 3 times the activity on the ends than in the middle. One difficulty that may result 
from this is the increased radiation to which the tissue at the ends of the stent will be exposed. 
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Figure 10: P-32 point sources on the outside surface 















The results of this research show that Pd-l03 may prove to be more efficient than P-32 at 
preventing restenosis beyond the ends of an irradiated stent. More research must be done before 
this can be concluded with more certainty. Currently, a study with a Pd-l03 irradiated stent is 
being done at Vanderbilt University to verify the above stated dosimetry. Once this is 
completed, the findings of that study along with the results from this study will be forwarded to a 
research group in Europe. This group has performed an intravenous ultrasound to determine the 
thicknesses of the various layers of the vessel walls. With the dosimetries they will be given and 
the ultrasound, they can determine the dose volume histogram for the real artery and hopefully, 
obtain results that will support the use ofPd-l03 and lead to clinical trials. 
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